EconPapers    
Economics at your fingertips  
 

Sample Size and Power for Cost-Effectiveness Analysis (Part 2)

Henry Glick ()

PharmacoEconomics, 2011, vol. 29, issue 4, 287-296

Abstract: Sample size and power for cost-effectiveness analysis depend on assumptions about the difference in cost and effect, the standard deviations of cost and effect, the correlation of the difference in cost and effect, the α and β errors and maximum willingness to pay (W). The first seven of these parameters share much in common in their effect on sample size and power for cost-effectiveness analysis, including that each is associated with a single pattern of power. W, on the other hand, is unique in that, when plotted for positive values, we can potentially observe any of six patterns of power associated with positive values of W. In addition, as W approaches ∞, power need be neither monotonically increasing nor decreasing and it can be multimodal. In this article, the relationship betweenWand sample size and power is explained. Copyright Adis Data Information BV 2011

Date: 2011
References: View references in EconPapers View complete reference list from CitEc
Citations: View citations in EconPapers (5)

Downloads: (external link)
http://hdl.handle.net/10.2165/11585080-000000000-00000 (text/html)
Access to full text is restricted to subscribers.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:pharme:v:29:y:2011:i:4:p:287-296

Ordering information: This journal article can be ordered from
http://www.springer.com/economics/journal/40273

DOI: 10.2165/11585080-000000000-00000

Access Statistics for this article

PharmacoEconomics is currently edited by Timothy Wrightson and Christopher I. Carswell

More articles in PharmacoEconomics from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().

 
Page updated 2025-03-20
Handle: RePEc:spr:pharme:v:29:y:2011:i:4:p:287-296